Detalhe da pesquisa
1.
Exagamglogene Autotemcel for Severe Sickle Cell Disease.
N Engl J Med
; 390(18): 1649-1662, 2024 May 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-38661449
2.
Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes.
N Engl J Med
; 385(9): 815-825, 2021 08 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-34437784
3.
Long-term safety and efficacy of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis and at least one F508del allele: 144-week interim results from a 192-week open-label extension study.
Eur Respir J
; 62(6)2023 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-37945033
4.
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele.
N Engl J Med
; 381(19): 1809-1819, 2019 11 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31697873
5.
A Phase 3 Open-Label Study of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 through 11 Years of Age with Cystic Fibrosis and at Least One F508del Allele.
Am J Respir Crit Care Med
; 203(12): 1522-1532, 2021 06 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33734030
6.
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
N Engl J Med
; 379(17): 1612-1620, 2018 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30334692
7.
VX-659-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
N Engl J Med
; 379(17): 1599-1611, 2018 10 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-30334693
8.
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial.
Lancet
; 394(10212): 1940-1948, 2019 11 23.
Artigo
em Inglês
| MEDLINE | ID: mdl-31679946
9.
Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer.
N Engl J Med
; 375(18): 1738-1748, 2016 11 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-27717303
10.
Pharmacokinetic interactions between the hepatitis C virus protease inhibitor boceprevir and ritonavir-boosted HIV-1 protease inhibitors atazanavir, darunavir, and lopinavir.
Clin Infect Dis
; 56(5): 718-26, 2013 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23155151
11.
Pharmacokinetic interaction between the hepatitis C virus protease inhibitor boceprevir and cyclosporine and tacrolimus in healthy volunteers.
Hepatology
; 56(5): 1622-30, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22576324
12.
Real-world safety and effectiveness of elexacaftor/tezacaftor/ivacaftor in people with cystic fibrosis: Interim results of a long-term registry-based study.
J Cyst Fibros
; 22(4): 730-737, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36963986
13.
Vorapaxar, an oral PAR-1 receptor antagonist, does not affect the pharmacokinetics and pharmacodynamics of warfarin.
Eur J Clin Pharmacol
; 68(11): 1509-16, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22476387
14.
Pharmacokinetics of the novel PAR-1 antagonist vorapaxar in patients with hepatic impairment.
Eur J Clin Pharmacol
; 68(11): 1501-8, 2012 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-22527342
15.
Pharmacokinetics and pharmacodynamics of the novel PAR-1 antagonist vorapaxar in patients with end-stage renal disease.
Eur J Clin Pharmacol
; 68(7): 1049-56, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22315147
16.
No differences in the pharmacodynamics and pharmacokinetics of the thrombin receptor antagonist vorapaxar between healthy Japanese and Caucasian subjects.
Eur J Clin Pharmacol
; 68(3): 291-300, 2012 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-21969227
17.
Assessment of potential pharmacokinetic interactions of ezetimibe/simvastatin and extended-release niacin tablets in healthy subjects.
Eur J Clin Pharmacol
; 67(5): 483-92, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21120461
18.
Clinical development of triple-combination CFTR modulators for cystic fibrosis patients with one or two F508del alleles.
ERJ Open Res
; 5(2)2019 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-31218221
19.
Pharmacokinetics of oral posaconazole in neutropenic patients receiving chemotherapy for acute myelogenous leukemia or myelodysplastic syndrome.
Pharmacotherapy
; 28(10): 1223-32, 2008 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-18823218
20.
An episode-based framework for analyzing health care expenditures: an application of reward renewal models.
Health Serv Res
; 40(6 Pt 1): 1953-71, 2005 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-16336558